SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Art of Investing
PICK 56.19-1.5%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sun Tzu who wrote (8241)9/19/2024 7:41:56 PM
From: Sun Tzu  Read Replies (1) of 10744
 
From: Sun Tzu3/15/2024 5:11:50 PM
Read Replies (1) of 8839
Aquestive Therapeutics AQST said its sublingual film epinephrine experimental drug Anaphylm showed exposure levels comparable to autoinjectors and was quicker to reach maximum concentration in a phase 3 study. Aquestive Therapeutics was up almost 2% pre-bell.

=====

JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating
Mar 15, 202409:44 EDT

AQST+16.00%
Aquestive Therapeutics AQST has an average buy rating and price target range of $7 to $10, according to analysts polled by Capital IQ.




.
.
.


.
.
The analysts raised their price target at the top.
But me, being ignorant of such matters, there were 10 purchases ranging from single digit starters to double, triple, and quad digits as the trend got clearer.

That's all.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News